DP
Diadema Partners Portfolio holdings
AUM
$161M
This Quarter Return
-0.06%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$125M
AUM Growth
+$125M
(+41%)
Cap. Flow
+$38M
Cap. Flow
% of AUM
30.38%
Top 10 Holdings %
Top 10 Hldgs %
68.21%
Holding
117
New
20
Increased
17
Reduced
6
Closed
31
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$18.9M |
| 2 |
Eli Lilly
LLY
|
$15.9M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$9M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.88M |
| 5 |
argenx
ARGX
|
$6.78M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$9.05M |
| 2 |
AbbVie
ABBV
|
$8.89M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
$5.6M |
| 5 |
AstraZeneca
AZN
|
$3.93M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.1B
| $18.9M | 4.94% |
+29,828
| New | +$18.9M |
|
|
2
Eli Lilly
LLY
$654B
| $15.9M | 4.16% |
+19,302
| New | +$15.9M |
|
|
3
Jazz Pharmaceuticals
JAZZ
$7.9B
| $10.8M | 2.82% |
87,189
+72,470
| +492% | +$9M |
|
4
TG Therapeutics
TGTX
$4.74B
| $8.2M | 2.14% |
207,883
+160,078
| +335% | +$6.31M |
|
|
5
argenx
ARGX
$43.6B
| $7.18M | 1.87% |
12,279
+11,600
| +1,708% | +$6.78M |
|
|
6
Neurocrine Biosciences
NBIX
$14.1B
| $6.88M | 1.8% |
+62,247
| New | +$6.88M |
|
7
Soleno Therapeutics
SLNO
$3.62B
| $6.64M | 1.73% |
93,002
+21,014
| +29% | +$1.5M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.3B
| $3.74M | 0.98% |
+52,877
| New | +$3.74M |
|
9
Alnylam Pharmaceuticals
ALNY
$59.4B
| $3.54M | 0.92% |
+13,115
| New | +$3.54M |
|
10
Vaxcyte
PCVX
$4.05B
| $3.49M | 0.91% |
92,385
+82,385
| +824% | +$3.11M |
|
11
Immunocore
IMCR
$1.66B
| $2.88M | 0.75% |
+96,984
| New | +$2.88M |
|
12
Rhythm Pharmaceuticals
RYTM
$7.03B
| $2.65M | 0.69% |
50,000
-25,000
| -33% | -$1.32M |
|
|
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
| $2.65M | 0.69% |
+60,000
| New | +$2.65M |
|
14
Viking Therapeutics
VKTX
$3.02B
| $2.51M | 0.66% |
+104,121
| New | +$2.51M |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.33B
| $2.36M | 0.62% |
164,048
+32,186
| +24% | +$463K |
|
16
Cogent Biosciences
COGT
$1.71B
| $2.35M | 0.61% |
392,213
+302,213
| +336% | +$1.81M |
|
17
Viridian Therapeutics
VRDN
$1.56B
| $2.18M | 0.57% |
162,063
+112,585
| +228% | +$1.52M |
|
18
Scholar Rock
SRRK
$3.19B
| $1.86M | 0.49% |
57,923
+4,763
| +9% | +$153K |
|
19
89bio
ETNB
$1.39B
| $1.68M | 0.44% |
+231,436
| New | +$1.68M |
|
20
Novo Nordisk
NVO
$250B
| $1.68M | 0.44% |
+24,618
| New | +$1.68M |
|
21
KalVista Pharmaceuticals
KALV
$708M
| $1.56M | 0.41% |
+135,509
| New | +$1.56M |
|
22
Apogee Therapeutics
APGE
$2.22B
| $1.49M | 0.39% |
40,000
-10,620
| -21% | -$397K |
|
|
SAGE
23
DELISTED
Sage Therapeutics
SAGE
| $1.46M | 0.38% |
+183,466
| New | +$1.46M |
|
24
VistaGen Therapeutics
VTGN
$110M
| $1.41M | 0.37% |
565,975
+123,455
| +28% | +$309K |
|
25
Ascendis Pharma
ASND
$12.2B
| $1.3M | 0.34% |
8,321
-16,955
| -67% | -$2.64M |
|